A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia

Figure 1

Flow diagram for patients in the study. AE, adverse event; AZL-M, azilsartan. 168, medoxomil; FAS, full analysis set; and PPS, per protocol set. ^∗One patient from the “treatment-naïve” group was considered only in the overall analysis. ^∗∗The same patient meeting multiple per protocol set exclusion criteria is counted under each criterion.